Pharmacological Inactivation of Src Family Kinases Inhibits LPS-Induced TNF-α Production in PBMC of Patients with Behçet’s Disease

Sevgi Irtegun,1 Gulsum Pektanc,1 Zeynep M. Akkurt,2 Mehtap Bozkurt,3 Fatih M. Turkcu,4 and Sevgi Kalkanli-Tas5

1Department of Medical Biology, Faculty of Medicine, Dicle University, 21280 Diyarbakır, Turkey
2Department of Dermatology, Faculty of Medicine, Dicle University, 21280 Diyarbakır, Turkey
3Department of Physical Therapy and Rehabilitation, Faculty of Medicine, Dicle University, 21280 Diyarbakır, Turkey
4Department of Ophthalmology, Faculty of Medicine, Dicle University, 21280 Diyarbakır, Turkey
5Department of Immunology, Faculty of Medicine, Dicle University, 21280 Diyarbakır, Turkey

Correspondence should be addressed to Sevgi Irtegun; irtegunsevgi@hotmail.com

Received 16 March 2016; Revised 19 May 2016; Accepted 29 May 2016

Academic Editor: Marc Pouliot

Copyright © 2016 Sevgi Irtegun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Behçet’s disease (BD) is a multisystemic chronic inflammatory disease characterized by relapsing oral and genital ulcers, uveitis, and skin lesions. The pathogenesis of BD is still unknown. Aberrant production of some cytokines/chemokines plays an important role in the pathogenesis of various inflammatory diseases. Revealing a key signaling regulatory mechanism involved in proinflammatory cytokines/chemokines production is critical for understanding of the pathogenesis of BD. The aim of this study was to determine the role of Src family kinases (SFKs) in production of some LPS-induced proinflammatory cytokines/chemokines in peripheral blood mononuclear cells (PBMC) of active BD patients. Chemical inhibition of SFKs activity impaired LPS-induced TNF-α production in PBMC of active BD patients, suggesting that modulating SFKs activity may be a potential target for BD treatment.

1. Introduction

Behçet’s disease (BD) is a chronic inflammatory disorder characterized by recurrent oral and genital ulcers, uveitis, and skin lesions [1, 2]. BD is a multisystemic disease due to involvement of central nervous and gastrointestinal systems, large vessels, joints, heart, and lungs [3]. Although the pathogenesis of the disease remains poorly understood, it is currently believed that immunological abnormalities triggered by some infectious and environmental factors in genetically susceptible individuals may play crucial roles during the pathogenesis of BD [2]. Indeed, an increasing amount of data has reported that immunological abnormalities are implicated in the BD pathophysiology [4–6].

Cytokines that mediate inflammatory and immune response play an important role in the pathogenesis of BD [2]. Elevated inflammatory response in BD appears to result from increased production of proinflammatory cytokines. Several lines of evidence supported the involvement of proinflammatory cytokines and chemokines in the disease pathogenicity and/or activity [4, 5]. The secretion of IL-6, IL-8, and TNF-α has been found to be increased in the serum of BD patients [7–9]. A study has reported that increased serum level of TNF-α is associated with active uveitis in BD patients [6]. Furthermore, a study has demonstrated that serum level of IL-8 which is a major chemokine involved in inflammation may be used as a serological marker for BD activity [10]. Similarly, a recent study has also demonstrated that serum level of IL-8 is elevated in active BD patients compared to inactive BD patients, suggesting that increased IL-8 level is associated with disease activity [11]. In another study, expression of IL-6 gene was found to be increased in active BD patients and IL-6 level was shown to increase in supernatant of cultured PBMC isolated from active BD patients [12].
Lipopolysaccharide (LPS) is a major component of the outer cell wall of Gram-negative bacteria causing acute inflammation. LPS binds to toll-like receptor-4 (TLR4) to exert its inflammatory action [13]. Ligation of TLR4 by LPS triggers activation of signaling cascades involved in inflammatory response [14, 15]. LPS stimulates the activation of immune system cells, including monocytes and macrophages [16, 17]. In cell culture, LPS elicits inflammatory response by rapidly inducing production of proinflammatory cytokines and chemokines, including TNF-\(\alpha\), IL-6, and IL-8 [12, 18]. Studies reported that Src family kinases (SFKs) are activated upon LPS stimulation and involved in LPS-induced TLR4 signaling pathway [14, 19]. It was reported that LPS-induced TNF-\(\alpha\) production in monocytes is regulated by SFKs activity. Chemical inhibition of these kinases impaired TNF-\(\alpha\) secretion in response to LPS [19]. Although it is known that SFKs are implicated in signaling pathways induced by LPS, the role of SFKs in LPS-induced cytokines/chemokines production has yet to be investigated in patients with BD.

In the present study, we have investigated whether SFKs are involved in LPS-induced TNF-\(\alpha\), IL-6, and IL-8 increase in PBMC of active BD patients. Age and sex matched healthy subjects were used as controls in the study.

2. Materials and Methods

2.1. Patients and Control Subjects. Twenty active BD patients (eleven male and nine female) were included in this study. The mean age of active BD patients was 31 years (range 20–41 years shown in Table 1). All patients fulfilled the criteria of the International Study Group for Behc¸et’s Disease [20]. All active BD patients were showing at least three of the major symptoms, including genital ulcers, oral ulcers, skin lesions, and uveitis (Table 1). When blood samples were removed from the BD patients during the active stage of disease, none of the patients was receiving any treatments. Twenty sex and age matched healthy subjects, eleven male and nine female, with a mean age of 31 years (range 20–41 years), were included as controls in the study. The study was approved by the local ethics committee, and written informed consents were taken from all patients and healthy subjects.

2.2. Reagents. RPMI 1640 medium, fetal bovine serum (FBS), L-glutamine, and penicillin/streptomycin were from Gibco by Life Technologies, UK. Ficoll-Paque Plus was from GE Healthcare, Sweden. Phosphate-buffered saline (PBS) was from HyClone, Logan, Utah. Dimethyl sulfoxide (DMSO) was from Santa Cruz Biotechnology, USA. PP2 (4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d] pyrimidine) was from Sigma Aldrich, USA. Lipopolysaccharides (LPS) from Escherichia coli 0111:B4 were from Sigma Aldrich, USA. BD vacutainer heparinized tubes were from BD Biosciences, UK. Enhanced chemiluminescence (ECL) was obtained from Bio-Rad, USA.

2.3. Antibodies. Anti-\(\beta\)-actin and anti-TNF-\(\alpha\) antibodies were from Abcam. Anti-Hck and Anti-Yes antibodies were from Santa Cruz Biotechnology. Anti-Lck, anti-Lyn, anti-Fyn, anti-c-Src, and anti-pTyr-416-SFKs antibodies were from Cell Signaling Technology. HRP-conjugated goat antimouse and goat anti-rabbit antibodies were from Abcam.
2.4. Cell Separation and Culture. Peripheral blood mononuclear cells (PBMC) were separated from 15 mL heparinized venous blood that was mixed with 15 mL PBS, using Ficoll-Paque Plus density gradient centrifugation [21]. The cells were washed twice in PBS and then resuspended in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and 100 units/mL penicillin/streptomycin (all from Life Technologies). The former cell suspensions were finally adjusted to a concentration of $2 \times 10^5$ cells/mL. All cells culture incubations were performed at 37°C in a humidified atmosphere containing 5% CO₂.

2.5. ELISA. PBMC were plated at $5 \times 10^5$ cells/well on a 96-well plate. To suppress the SFKs activity, PBMC were treated with $10 \mu M$ PP2, a selective and potent SFKs inhibitor, for 1 h before 100 ng/mL LPS stimulation for 18 h. The cells were treated with DMSO to be used as control. Supernatants were harvested after 18 h and examined for concentrations of TNF-α, IL-6, and IL-8 by ELISA (BOSTER Immunoleader, USA) following the manufacturers’ instructions. Absorbance was read at 450 nm on a spectrophotometric plate reader (Multiskan GO, Thermo Scientific) and analyzed using the SkanIt software program. The limits of detection for individual cytokines and chemokines were as follows: TNF-α, 15.6 pg/mL; IL-6, 4.69 pg/mL; IL-8, 15.6 pg/mL.

2.6. Western Blot Analysis. PBMC were plated at $5 \times 10^5$ cells/well on a 6-well plate. To suppress the SFKs activity, PBMC were treated with $10 \mu M$ PP2 for 1 h before 100 ng/mL LPS stimulation for 15 min. The cells were treated with DMSO to be used as control. After treatments, the cells were washed with ice-cold PBS and lysed on ice in RIPA buffer (Sigma Aldrich) supplemented with protease and phosphatase inhibitor cocktail (Thermo Scientific). Total cellular protein concentration was determined using a BCA protein assay kit according to the manufacturer’s instructions (Pierce, Thermo Scientific). Total cellular proteins (20 μg) were separated by 10% SDS-PAGE gel and separated proteins from the SDS-PAGE were transferred onto polyvinyl difluoride (PVDF) membrane (Bio-Rad). Nonspecific binding was blocked by membrane incubation in PBS with 5% nonfat dried milk and 0.05% Tween-20 for 1 h at room temperature. The membranes were probed with primary antibodies for 2 h at room temperature. The total protein levels of Src family members (Hck, Lyn, Fyn, c-Src, Lck, and Yes) and TNF-α were detected with antibodies against the indicated proteins. β-actin was used as a loading control. Phosphorylation levels of SFKs were detected using anti-pTyr-416-SFKs antibody. In the literature, phosphorylation level of Tyr-416 has been extensively used as a critical determinant of SFKs catalytic activity [22–26]. Appropriate HRP-conjugated secondary antibodies were used to visualize the specific bands. The protein bands were visualized using ECL (Bio-Rad) according to the manufacturer’s instruction. The images were taken using ChemiDoc™ MP (Bio-Rad).

2.7. Statistical Analysis. Significance of the results has been evaluated by Student’s $t$-test using the SigmaPlot 12 software package (Systat). A $p$ value of $< 0.05$ was considered statistically significant.

3. Results

It was found that Hck, Lyn, Fyn, c-Src, Lck, and Yes were expressed abundantly in PBMC of active BD patients (Figure 1). However, there was no detectable expression of Blk and Fgr, which are other Src family members (data not shown). While LPS stimulation led to an increase in SFKs activity, SFKs activity was abolished by PP2 treatment in PBMC of active BD patients (Figure 1).

ELISA results showed that suppression of SFKs activity by PP2 blocked LPS-induced TNF-α increase in the PBMC of both controls and active BD patients (Figure 2(a)). However, the inhibition of SFKs activity had no significant effect on LPS-induced IL-6 and IL-8 release (Figures 2(b) and 2(c)). Similar results were obtained with Western Blotting. The results showed that LPS stimulation led to a dramatic increase in TNF-α protein level of PBMC of active BD patients compared to PBMC of control. However, suppressing the SFKs activity by PP2 inhibited LPS-induced TNF-α increase (Figure 3). As a result, inhibition of SFKs activity in PBMC of active BD patients impaired TNF-α production upon LPS treatment.
4. Mediators of Inflammation

**Control**

![Control](image1)

**BD patient**

![BD patient](image2)

![Control](image3)

![BD patient](image4)

![Control](image5)

![BD patient](image6)

![Control](image7)

![BD patient](image8)

**Figure 2:** The effect of the PP2 on LPS-induced cytokine/chemokine production in PBMC. $0.5 \times 10^6$ PBMC were treated with $10 \mu M$ PP2 for 1 h prior to stimulation with $100 \text{ ng/mL}$ LPS for 18 h. Supernatants were collected and cytokine/chemokine levels determined by ELISA; TNF-$\alpha$ (a), IL-6 (b), and IL-8 (c). The results are presented as pooled data from three independent experiments. The statistical significance of the data was analyzed by Student’s $t$-test.

**4. Discussion**

In this study, we demonstrated for the first time the functional significance of SFKs activity in the LPS-induced TNF-$\alpha$ production in PBMC of active BD patients. Studies have reported that SFKs are involved in inflammatory diseases, including rheumatoid arthritis and osteoarthritis [27, 28], but the role of SFKs in the pathogenesis of BD has not been investigated yet. To our knowledge, there is no report available on the role of SFKs in LPS-induced cytokines/chemokines production in PBMC of active BD patients.

Here we showed that six SFK members (Hck, Lyn, Fyn, c-Src, Lck, and Yes) are expressed in PBMC, but Fgr and Blk are not expressed at detectable levels (data not shown). We found that LPS stimulation led to an increase in SFKs activity. This result is in good agreement with previous studies reporting
that LPS induces activation of SFKs [17–19]. The role of SFKs in LPS-induced production of TNF-α in monocytes and macrophages is reported in literature [19, 29, 30]. However, a definitive evidence for a role of SFKs in PBMC of BD patients remains unknown. It is known that PBMC can be stimulated by LPS to produce high amounts of cytokines/chemokines, such as TNF-α, IL-6, and IL-8 [19, 31]. Toll-like receptors (TLR) play an important role in pathogen recognition and activation of innate immunity. Engagement of TLR4 by LPS induces activation of signaling pathways leading to increased inflammatory cytokines/chemokines production [14, 15, 31, 32]. Some evidence showed that SFKs are involved in signaling pathways triggered by LPS [17, 18, 32].

We observed that PBMC of active BD patients showed a significant response compared to healthy subjects upon LPS stimulation. Stimulation of PBMC with LPS resulted in a significant increase in TNF-α production, but this increase in PBMC of BD patients was much higher compared to healthy subjects used as controls. We found that inhibition of SFKs activity by PP2 dramatically blocked LPS-induced TNF-α release. TNF-α is the most important cytokine in the initiation and progression of inflammatory disease. As TNF-α is involved in the pathogenesis of chronic inflammatory conditions, an increased TNF-α level is associated with destructive inflammatory process in many inflammatory diseases, including BD [33–35]. Indeed, previous studies reported increased serum level of TNF-α in active BD patients [36, 37]. Our results suggest that SFKs activity is required for LPS-induced TNF-α production in PBMC of active BD patients.

It is known that LPS-induced TLR4 signaling leads to an increase in TNF-α protein level [38]. Here we also showed that TNF-α protein level was increased in response to LPS stimulation. Interestingly, PBMC of BD patients gave a much higher response to the LPS stimulation than PBMC of controls. The amount of TNF-α protein level in PBMC of BD patients was significantly increased compared to PBMC of healthy subjects upon LPS stimulation. LPS-induced TNF-α production was suppressed by chemical inhibition of SFKs activity. This result indicates that PBMC of BD patients is more prone to production of inflammatory TNF-α cytokine associated with inflammatory disorders and SFKs activity is necessary for LPS-induced TNF-α production in PBMC of active BD patients. To our knowledge, this is the first example showing the pharmacological inhibition of SFKs activity is able to modulate LPS-induced TNF-α production in PBMC of active BD patients.

Herein, we showed that IL-6 and IL-8 levels in PBMC of BD patients were also increased in response to LPS stimulation. A previous study reported that LPS-induced IL-6 production was reduced by 50% upon PP2 treatment in primary human macrophages [19]. However, our results revealed that LPS-induced IL-6 and IL-8 production were not significantly affected by the chemical inhibition of SFKs activity. One possible explanation for this result is that SFKs have a differential effect on LPS-induced inflammatory cytokines production in PBMC. SFKs might be a potential future drug target for BD treatment. Further study is required to elucidate which SFKs members are exactly required for regulation of TLR4 involved signaling pathways in BD.

5. Conclusion

In conclusion, this study has investigated the role of SFKs on LPS-induced inflammatory cytokines/chemokines production in PBMC of active BD patients. Blocking SFKs activity by PP2 resulted in inhibition of LPS-induced TNF-α production, suggesting that SFKs are a key component of TLR4 involved signaling pathways. Further study is required to elucidate which SFKs members are exactly required for regulation of TLR4 involved signaling pathways in BD. Taken together, SFKs might be a potential future drug target for BD treatment.

Competing Interests

The authors declare that there are no competing interests regarding the publication of this paper.

Acknowledgments

This work was supported by Grant 213S016 from the Scientific and Technological Research Council of Turkey. The authors thank Kadir Demircan for critical reading of the paper.

References

[1] H. Yazici, “The lumps and bumps of Behc¸et’s syndrome,” Autoimmunity Reviews, vol. 3, supplement 1, pp. S53–S54, 2004.

[2] Z. Y. Zhou, S. L. Chen, N. Shen, and Y. Lu, “Cytokines and Behc¸et’s disease,” Autoimmunity Reviews, vol. 11, no. 10, pp. 699–704, 2012.

[3] S. Yurdakul and H. Yazici, “Behc¸et’s syndrome,” Best Practice & Research: Clinical Rheumatology, vol. 22, no. 5, pp. 793–809, 2008.

[4] H. Houman, A. Hamzaoui, I. B. Ghorbal, M. Khanfir, M. Feki, and K. Hamzaoui, "Abnormal expression of chemokine receptors in Behc¸et’s disease: relationship to intracellular Th1/Th2 cytokines and to clinical manifestations;" Journal of Autoimmunity, vol. 23, no. 3, pp. 267–273, 2004.

[5] H. Belguendouz, K. Lahmar-Belguendouz, D. Messaoudene et al., “Modulate the ‘Immune-Metabolism’ interactions during behc¸et disease: effect on arginine metabolism,” International Journal of Inflammation, vol. 2015, Article ID 241738, 9 pages, 2015.

[6] M. Mesquida, B. Molins, V. Llorente et al., “Proinflammatory cytokines and C-reactive protein in uveitis associated with Behc¸et’s disease,” Mediators of Inflammation, vol. 2014, Article ID 396204, 8 pages, 2014.

[7] J.-L. Mege, N. Dilsen, V. Sanguedolce et al., “Overproduction of monocyte derived tumor necrosis factor α, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behc¸et’s disease. A comparative study with familial Mediterranean fever and healthy subjects;” The Journal of Rheumatology, vol. 20, no. 9, pp. 1544–1549, 1993.

[8] A. Sun, Y.-P. Wang, J.-S. Chia, B.-Y. Liu, and C.-P. Chiang, "Treatment with levamisole and colchicine can result in a significant reduction of IL-6, IL-8 or NF-kB level in patients with mucocutaneous type of Behc¸et’s disease;" Journal of Oral Pathology and Medicine, vol. 38, no. 5, pp. 401–405, 2009.
[9] M. O. Oztas, M. Onder, M. A. Gurer, N. Bukan, and B. Sancak, "Serum interleukin 18 and tumour necrosis factor-α levels are increased in Behc¸et's disease," Clinical and Experimental Dermatology, vol. 30, no. 1, pp. 61–63, 2005.

[10] J. Katsantonis, Y. Adler, C. E. Orfanos, and C. C. Zouboulis, "Adamantiaides-Behc¸et's disease: serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate," Dermatology, vol. 201, no. 1, pp. 37–39, 2000.

[11] Z. M. Akkurt, M. Bozkurt, D. Uc¸mak et al., "Serum cytokine levels in Behc¸et's disease," Journal of Clinical Laboratory Analysis, vol. 29, no. 4, pp. 317–320, 2015.

[12] Y. Yamakawa, Y. Sugita, T. Nagatani et al., "Interleukin-6 (IL-6) in patients with Behc¸et's disease," Journal of Dermatological Science, vol. 11, no. 3, pp. 189–195, 1996.

[13] E. Faure, O. Equils, P. A. Sieling et al., "Bacterial lipopolysaccharide activates NF-κB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells," The Journal of Biological Chemistry, vol. 275, no. 15, pp. 11058–11063, 2000.

[14] P. Gong, D. J. Angelini, S. Yanget al., "TLR4 signaling is coupled to SRC family kinase activation, tyrosine phosphorylation of zonula adherens proteins, and opening of the paracellular pathway in human lung microvascular endothelia," The Journal of Biological Chemistry, vol. 283, no. 19, pp. 13437–13449, 2008.

[15] T. K. Means, D. T. Golenbock, and M. J. Fenton, "The biology of Toll-like receptors," Cytokine and Growth Factor Reviews, vol. 11, no. 3, pp. 219–232, 2000.

[16] T. Suzuki, S.-I. Hashimoto, N. Toyoda et al., "Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE," Blood, vol. 96, no. 7, pp. 2584–2591, 2000.

[17] J. L. Kang, W. L. Hye, J. K. Hee et al., "Inhibition of Src tyrosine kinases suppresses activation of nuclear factor-κB, and serine and tyrosine phosphorylation of IkB-α in lipopolysaccharide-stimulated raw 264.7 macrophages," Journal of Toxicology and Environmental Health A, vol. 68, no. 19, pp. 1634–1662, 2005.

[18] G. Napolitani, N. Bortoletto, L. Racioppi, A. Lanzavecchia, and U. D’Oro, "Activation of src-family tyrosine kinases by LPS regulates cytokine production in dendritic cells by controlling AP-1 formation," European Journal of Immunology, vol. 33, no. 10, pp. 2832–2841, 2003.

[19] M. J. Smolinska, T. H. Page, T. Smallle, and B. M. J. Foxwell, "Chemical inhibition of Src family kinases affects major LPS-activated pathways in primary human macrophages," Molecular Immunology, vol. 45, no. 4, pp. 990–1000, 2008.

[20] International Study Group for Behc¸et’s Disease, "Criteria for diagnosis of Behc¸et’s disease," The Lancet, vol. 335, no. 8697, pp. 1078–1080, 1990.

[21] E. A. Cetin, F. Cosan, U. C. Kucuksezer et al., "Behc¸et’s disease: immunological relevance with arthritis of ankylosing spondylitis," Rheumatology International, vol. 33, no. 3, pp. 733–741, 2013.

[22] V. G. Brunton, E. Avizienyte, V. J. Fincham et al., "Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior," Cancer Research, vol. 65, no. 4, pp. 1335–1342, 2005.

[23] M. Canel, A. Serrelts, D. Miller et al., “Quantitative in vivo imaging of the effects of inhibiting integrin signaling via Src and FAK on cancer cell movement: effects on E-cadherin dynamics,” Cancer Research, vol. 70, no. 22, pp. 9413–9422, 2010.

[24] A. Ostareck-Lederer, D. H. Ostareck, C. Cans et al., "c-Src-mediated phosphorylation of hnRNP K drives translational activation of specifically silenced mRNAs," Molecular and Cellular Biology, vol. 22, no. 13, pp. 4535–4543, 2002.

[25] B. Serrelts, A. Serrelts, S. M. Mason et al., "A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model," Carcinogenesis, vol. 30, no. 2, pp. 249–257, 2009.

[26] S. Irgun, R. J. Wood, A. R. Ormbay, T. D. Mulhern, and D. M. Hatters, "Tyrosine 416 is phosphorylated in the closed, repressed conformation of c-Src," PLoS ONE, vol. 8, no. 7, Article ID e71035, 2013.

[27] H. Marotte, S. Ahmed, J. H. Ruth, and A. E. Koch, "Blocking ERK-1/2 reduces tumor necrosis factor α-induced interleukin-18 bioactivity in rheumatoid arthritis synovial fibroblasts by induction of interleukin-18 binding protein A," Arthritis & Rheumatism, vol. 62, no. 3, pp. 722–731, 2010.

[28] M. A. Amin, B. J. Rabquer, P. J. Mansfield et al., "Interleukin 18 induces angiogenesis in vitro and in vivo via Src and Jnk kinases," Annals of the Rheumatic Diseases, vol. 69, no. 12, pp. 2204–2212, 2010.

[29] I. Štefanová, M. L. Corcoran, E. M. Horak, L. M. Wahl, J. B. Bolen, and I. D. Horak, "Lipopolysaccharide induces activation of CD14-associated protein tyrosine kinase p53/56lyn," The Journal of Biological Chemistry, vol. 268, no. 28, pp. 20725–20728, 1993.

[30] J. Check, C. L. Byrd, J. Menio, R. A. Rippe, I. N. Hines, and M. D. Wheeler, "Src kinase participates in LPS-induced activation of NADPH oxidase," Molecular Immunology, vol. 47, no. 4, pp. 756–762, 2010.

[31] L. Y. Chen, B. L. Zuraw, M. Zhao, F. T. Liu, S. Huang, and Z. K. Pan, "Involvement of protein tyrosine kinase in toll-like receptor 4-mediated NF-κB activation in human peripheral blood monocytes," American Journal of Physiology: Lung Cellular and Molecular Physiology, vol. 284, no. 4, pp. L607–L613, 2003.

[32] M. J. Smolinska, T. H. Page, A. M. Urbania¸bi, B. E. Mutch, and N. J. Horwood, "Hck tyrosine kinase regulates TLR4-induced TNF and IL-6 production via AP-1," The Journal of Immunology, vol. 187, no. 11, pp. 6043–6051, 2011.

[33] R. Karadag, C. Koca, Y. Totan et al., "Comparison of serum levels of IL-6, IL-8, TNF-α, C reactive protein and heat shock protein 70 in patients with active or inactive Behc¸et’s disease," Turkish Journal of Medical Sciences, vol. 40, pp. 57–62, 2010.

[34] J. Wang, Q. Zhao, G. Wang et al., "Circulating levels of Th1 and Th2 chemokines in patients with ankylosing spondylitis," Cytokine, vol. 81, pp. 10–14, 2016.

[35] I. B. McInnes and G. Schett, "Cytokines in the pathogenesis of rheumatoid arthritis," Nature Reviews Immunology, vol. 7, no. 6, pp. 429–442, 2007.

[36] C. Evereklioglu, H. Er, Y. Türköz, and M. Çekmen, "Serum levels of TNF-α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behc¸et’s disease," Mediators of Inflammation, vol. 11, no. 2, pp. 87–93, 2002.

[37] Y. Ozdamar, N. Berker, G. Bahar et al., "Inflammatory mediators and posterior segment involvement in ocular Behc¸et disease,"
[38] C. D. Dumitru, J. D. Ceci, C. Tsatsanis et al., “TNF-α induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway,” Cell, vol. 103, no. 7, pp. 1071–1083, 2000.